PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
People with estrogen receptor-positive, her2-negative early breast cancer are asked to participate in a research study being conducted by Queens Hospital Center.
You may be eligible to participate in this study if you:
• Are a male or female at least 18 years of age
• Have documented ER tumor by immunohistochemistry
• Have documented HER2 tumor
• Have undergone definitive surgery of the primary breast tumor(s)
• Have received or will be receiving adjuvant chemotherapy and have completed adjuvant chemotherapy
• Have received (neo)adjuvant chemotherapy and/or had surgery and had no prior endocrine therapy
• Have confirmed availability of an untreated primary breast tumor tissue specimen
• Have adequate organ function
You may NOT participate in this study if you:
• Have been receiving or planning to receive a CDK4/6i as adjuvant therapy
• Have been diagnosed with Stage IV breast cancer
• Have active cardiac disease or history of cardiac dysfunction
• Have received treatment with investigational therapy within 28 days
• Have had a serious infection requiring oral or IV antibiotics within 14 days (e.g., COVID-19)
• Are pregnant or breastfeeding
Contact Information
Linda Bulone, Study Coordinator
Phone: (718) 883-3751
Email: BULONEL@NYCHHC.ORG
21-06-558